Comparing Melanoma Immunotherapy Outcomes in Key Clinical Trials
Source: Targeted Oncology, May 2025
During a live event, Ahmad Tarhini, MD, PhD, discussed key melanoma trials with varying survival and toxicity profiles.
This article is part 1 of a 2-part series from a Case-Based Roundtable event.
CASE SUMMARY
- A 78-year-old man with a history of stage III melanoma underwent surgical resection 12 years ago.
- The patient presented with fatigue and asthenia that limited his daily activities.
- ECOG performance status:
- Physical examination unremarkable
- Notable laboratory findings: lactate dehydrogenase level of 380 U/L (reference range, 110-240 U/L)
- CT imaging: pulmonary and hepatic nodules
- Brain MRI: no evidence of brain metastases
- Core needle biopsy of the largest hepatic lesion (2 cm): melanoma